Cargando…

Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer

BACKGROUND: This study investigated the predictive value of circulating microRNA-126 (cir-miRNA-126) in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy combined with bevacizumab. METHODS: The study included 68 patients. Blood samples (plasma) were collected bef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hansen, T F, Carlsen, A L, Heegaard, N H H, Sørensen, F B, Jakobsen, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333496/ https://www.ncbi.nlm.nih.gov/pubmed/25584492 http://dx.doi.org/10.1038/bjc.2014.652

Ejemplares similares

The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
por: Hansen, Torben Frøstrup, et al.
Publicado: (2012)

MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy
por: Hansen, Torben Frøstrup, et al.
Publicado: (2019)

MicroRNA-126 and epidermal growth factor-like domain 7–an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial
por: Hansen, T F, et al.
Publicado: (2013)

Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
por: Hansen, Torben Frøstrup, et al.
Publicado: (2017)

Prognostic significance of circulating microRNA-214 and -126 in dogs with appendicular osteosarcoma receiving amputation and chemotherapy
por: Heishima, Kazuki, et al.
Publicado: (2019)

Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer
por: Thomsen, Caroline B., et al.
Publicado: (2020)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
por: Geva, Ravit, et al.
Publicado: (2013)

Circulating plasma microRNA-126, microRNA-145, and microRNA-155 and their association with atherosclerotic plaque characteristics
por: Knoka, Evija, et al.
Publicado: (2020)

Intra-tumoural vessel area estimated by expression of epidermal growth factor-like domain 7 and microRNA-126 in primary tumours and metastases of patients with colorectal cancer: a descriptive study
por: Hansen, Torben Frøstrup, et al.
Publicado: (2015)

Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension
por: Wuttge, Dirk M, et al.
Publicado: (2021)

Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer
por: Wu, Qian, et al.
Publicado: (2013)

Circulating microRNA-214 and -126 as potential biomarkers for canine neoplastic disease
por: Heishima, Kazuki, et al.
Publicado: (2017)

Human Circulating MicroRNA-1 and MicroRNA-126 as Potential Novel Indicators for Acute Myocardial Infarction
por: Long, Guangwen, et al.
Publicado: (2012)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
por: Boisen, Mogens K., et al.
Publicado: (2014)

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX
por: Kiss, I., et al.
Publicado: (2017)

The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort
por: Hansen, Torben Frøstrup, et al.
Publicado: (2014)

Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease
por: Scullion, Kathleen M., et al.
Publicado: (2020)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo, Maria, et al.
Publicado: (2015)

Circulating microRNA-126 in patients with coronary artery disease: correlation with LDL cholesterol
por: Sun, Xiao, et al.
Publicado: (2012)

Changes in circulating microRNA-126 levels are associated with immune imbalance in children with acute asthma
por: Tian, Man, et al.
Publicado: (2018)

The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients
por: Moisuc, Diana Cornelia, et al.
Publicado: (2023)

Acute Effects of Different Exercise Protocols on the Circulating Vascular microRNAs -16, -21, and -126 in Trained Subjects
por: Wahl, Patrick, et al.
Publicado: (2016)

Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancer
por: Hagman, Helga, et al.
Publicado: (2018)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
por: Bencsikova, Beatrix, et al.
Publicado: (2015)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)

The Role of Circulating MicroRNA-126 (miR-126): A Novel Biomarker for Screening Prediabetes and Newly Diagnosed Type 2 Diabetes Mellitus
por: Liu, Yang, et al.
Publicado: (2014)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
por: Dinu, Ioana Mihaela, et al.
Publicado: (2023)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

MicroRNA-126 contributes to Niaspan treatment induced vascular restoration after diabetic retinopathy
por: Wang, Yang, et al.
Publicado: (2016)

MicroRNA-214 and MicroRNA-126 Are Potential Biomarkers for Malignant Endothelial Proliferative Diseases
por: Heishima, Kazuki, et al.
Publicado: (2015)

Circulating microRNA-126 as an Independent Risk Predictor of Coronary Artery Disease: A Case-Control Study
por: Ali, Wahid, et al.
Publicado: (2021)

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
por: Li, Zhigui, et al.
Publicado: (2018)

Use of Bevacizumab in Metastatic Colorectal Cancer: Report from the Mexican Opinion and Analysis Forum on Colorectal Cancer Treatment with Bevacizumab (September 2009)
por: Zinser-Sierra, Juan W., et al.
Publicado: (2012)

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2018)

Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer
por: van Nassau, Sietske C., et al.
Publicado: (2021)

Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients
por: Wang, Yixing, et al.
Publicado: (2021)

Diurnal Variations of Human Circulating Cell-Free Micro-RNA
por: Heegaard, Niels H. H., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6ahk7j35q1ic4g7hbqv2n4pg19